Recent advances and novel agents for gastrointestinal stromal tumor (GIST)

Gurpreet Lamba, Samir Ambrale, Byung Lee, Ridhi Gupta, Shamudheen M. Rafiyath, Delong Liu

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations

Abstract

The discovery of CD117 mutation in almost all gastrointestinal stromal tumors (GISTs) marked a milestone. Other spindle cell neoplasms arising from the GI tract including lipoma, schwannoma, hemangioma, leiomyoma, and leiomyosarcoma are typically CD117-negative. GIST research and clinical care now represent a paradigm of translating discoveries in the molecular pathogenesis of cancer into highly effective targeted therapies that selectively inhibit etiologic driver pathways, leading to dramatically improved clinical outcomes. A series of investigations and trials are underway to develop novel and effective ways to treat patients with GIST. In this review, we discuss the highlights of recent advances and novel agents for GIST therapy.

Original languageEnglish (US)
Article number21
JournalJournal of Hematology and Oncology
Volume5
DOIs
StatePublished - 2012
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Recent advances and novel agents for gastrointestinal stromal tumor (GIST)'. Together they form a unique fingerprint.

Cite this